ATE279212T1 - 2-methoxyestradiol-induzierte apoptosis in krebszellen - Google Patents

2-methoxyestradiol-induzierte apoptosis in krebszellen

Info

Publication number
ATE279212T1
ATE279212T1 AT97934286T AT97934286T ATE279212T1 AT E279212 T1 ATE279212 T1 AT E279212T1 AT 97934286 T AT97934286 T AT 97934286T AT 97934286 T AT97934286 T AT 97934286T AT E279212 T1 ATE279212 T1 AT E279212T1
Authority
AT
Austria
Prior art keywords
methoxyestradiol
cancer cells
treatment
meoe2
induced apoptosis
Prior art date
Application number
AT97934286T
Other languages
German (de)
English (en)
Inventor
Tapas Mukhopadhyay
Jack A Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE279212T1 publication Critical patent/ATE279212T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97934286T 1996-07-30 1997-07-24 2-methoxyestradiol-induzierte apoptosis in krebszellen ATE279212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/688,613 US5958892A (en) 1996-07-30 1996-07-30 2-methoxyestradiol-induced apoptosis in cancer cells
PCT/US1997/012998 WO1998004291A1 (en) 1996-07-30 1997-07-24 2-methoxyestradiol-induced apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
ATE279212T1 true ATE279212T1 (de) 2004-10-15

Family

ID=24765087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934286T ATE279212T1 (de) 1996-07-30 1997-07-24 2-methoxyestradiol-induzierte apoptosis in krebszellen

Country Status (8)

Country Link
US (3) US5958892A (enExample)
EP (1) EP0921821B1 (enExample)
JP (1) JP2000517299A (enExample)
AT (1) ATE279212T1 (enExample)
AU (1) AU723401B2 (enExample)
CA (1) CA2262533A1 (enExample)
DE (1) DE69731213T2 (enExample)
WO (1) WO1998004291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
US6548541B1 (en) * 1999-04-21 2003-04-15 Unitech Pharmaceuticals, Inc. Carboplatin analogs for cancer treatment
CA2373637A1 (en) * 1999-05-12 2000-11-16 Russell T. Turner Treatment of bone cancer
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
WO2002036624A2 (en) * 2000-10-30 2002-05-10 Board Of Regents, The University Of Texas System Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof
WO2002062349A1 (en) * 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells
DK1373215T3 (da) * 2001-03-30 2006-11-13 Us Health Gelanamycinderivater egnet til behandling af cancer
WO2003063787A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
UA81634C2 (ru) 2002-07-18 2008-01-25 Хеликс Биофарма Корп. Фармацевтическая композиция уреазы для ингибирования роста раковых клеток и ее применение
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7160908B2 (en) * 2003-03-04 2007-01-09 Unitech Pharmaceuticals, Inc. Dynamic anticancer platinum compounds
EP1633367A2 (en) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2580264A1 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
WO2008150550A1 (en) * 2007-06-05 2008-12-11 Cornell University Compounds for enhancing p21 expression and methods of use thereof
KR20090009637A (ko) * 2007-07-20 2009-01-23 삼성전자주식회사 엠비-오에프디엠 시스템 및 프레임 바운더리 검출 방법
CN109069644B (zh) * 2015-10-08 2022-10-28 犹他大学研究基金会 用于预防或治疗癌症的方法和组合物
KR101837735B1 (ko) * 2016-08-08 2018-04-19 성균관대학교산학협력단 TCTP (Translationally controlled tumour protein) 단백질을 포함하는 난모세포(oocytes) 노화 방지 또는 수정능력 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
JPH03505675A (ja) 1988-10-31 1991-12-12 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 新生表現型の抑制を制御する産生体及び方法
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
EP0390323B2 (en) 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
IE20010427A1 (en) 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.

Also Published As

Publication number Publication date
AU3738397A (en) 1998-02-20
CA2262533A1 (en) 1998-02-05
JP2000517299A (ja) 2000-12-26
EP0921821B1 (en) 2004-10-13
EP0921821A1 (en) 1999-06-16
AU723401B2 (en) 2000-08-24
US5958892A (en) 1999-09-28
DE69731213D1 (de) 2004-11-18
WO1998004291A1 (en) 1998-02-05
DE69731213T2 (de) 2006-02-23
US20030099614A1 (en) 2003-05-29
US6410029B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
DE69731213D1 (de) 2-methoxyestradiol-induzierte apoptosis in krebszellen
Nogueira et al. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
NO885769D0 (no) Fremgangsmaate for lagring, utdeling og applisering av kirurgiske heftstifter.
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
ATE273386T1 (de) Menschliches cyclin e
NO860371L (no) Fremgangsmaate ved fremstilling av peptidaseinhibitorer.
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
CA2259960A1 (en) Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
ES2161655A1 (es) Procedimiento para determinar la capacidad invasiva y metastasica de un tumor epitelial mediante el uso de snail.
PL346246A1 (en) Modulating multiple lineage kinase proteins
EE03771B1 (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
NO20005548D0 (no) Mykobakterieinhibitorer
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
BR0113266A (pt) Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
WO2001023522A8 (en) Compositions and methods for p53-mediated repression of gene expression
EP1135141A4 (en) PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER
AU6727598A (en) In vitro determination for detection of tumors of the intestine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties